SCHEMBL5409216

SCHEMBL5409216

COc1ccccc1/C=C/S(=O)(=O)O.NC(=O)c1ccc(Br)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.49
NFE2L2 Q16236 8/20 0.46
KCNH2 Q12809 1/20 0.43
MAPT P10636 2/20 0.42
RECQL P46063 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
PTGES2 Q9H7Z7 1/20 0.42
LY96 Q9Y6Y9 1/20 0.42
MAOB P27338 1/20 0.42
TFEB P19484 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416380 0.89 AR (0.49) ARNFE2L2MAPTCA12CA9
SCHEMBL4618136 0.89 NFE2L2 (0.48) NFE2L2KCNH2MAPTRECQLPTGES2
SCHEMBL5416929 0.88 PTGES2 (0.48) ARNFE2L2KCNH2MAPTRECQL
SCHEMBL4619057 0.86 CA12 (0.48) NFE2L2KCNH2CA12CA9PTGES2
SCHEMBL27717778 0.86 CA12 (0.48) NFE2L2KCNH2CA12CA9PTGES2
SCHEMBL5409079 0.83 PTGES2 (0.50) ARNFE2L2PTGES2LY96TFEB
SCHEMBL5409655 0.83 NPC1 (0.48) NFE2L2KCNH2MAPTRECQLPTGES2
SCHEMBL5414749 0.83 LY96 (0.44) ARNFE2L2MAPTPTGES2LY96
SCHEMBL5409218 0.82 AR (0.48) ARNFE2L2KCNH2MAPTRECQL
SCHEMBL5409213 0.82 AR (0.48) ARNFE2L2KCNH2MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 AR 1575/4885NFE2L2 1842/4885KCNH2 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.